Loading
Instead of finding a different target for each cancer, hit the scaffolding cells that almost all solid tumours share.
Rather than finding a different target for each cancer, this idea hits the cancer-associated fibroblasts that almost all solid tumours share. FAP-targeted alpha or beta radioligands such as FAP-2286 would be given to FAPI-PET-avid pancreatic, gastric and sarcoma patients irrespective of tumour-cell genotype, delivering radiation to the stroma with crossfire into adjacent tumour cells and depleting the fibroblasts that exclude T cells. Stroma is genetically stable, so resistance mutations are not expected. The test is phase 2 FAP-2286 cohorts selected by FAPI PET, with paired biopsies and a PD-1 combination in pancreatic cancer. At early-clinical maturity it addresses the bottleneck Cold tumours and the immunosuppressive microenvironment.
Shares A university cyclotron network with shared regulatory files for new tracers, FAP-2286 (177Lu / 68Ga), FAPI PET, FAP.
Shares FAP, Targeted alpha therapy, Radioligand therapy (beta emitters), Sarcomas (soft tissue, bone, GIST).
Shares FAP-2286 (177Lu / 68Ga), FAPI PET, Radioligand therapy (beta emitters).
Shares FAP-2286 (177Lu / 68Ga), FAPI PET, Radioligand therapy (beta emitters).
Shares A university cyclotron network with shared regulatory files for new tracers, FAPI PET, FAP.
Shares FAP-2286 (177Lu / 68Ga), FAPI PET, Radioligand therapy (beta emitters).
Shares FAPI PET, FAP, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.
Shares Reprogramme the stroma rather than remove it: second-generation stromal trials with a stromal biomarker and a survival endpoint, FAPI PET, FAP, Radioligand therapy (beta emitters).